HOWL biotech catalysts & pipeline

WEREWOLF THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

WTX-124 — Topline data

H2 2026

In the second half of the year, we expect to provide additional updates on the strategic alternatives process that is being run with assistance from our exclusive financial advisor, Piper Sandler & Co. ("Piper Sandler"), as well as data updates on our clinical trials of WTX-124 and WTX-330.

Source filing

WTX-330 — Topline data

H2 2026

In the second half of the year, we expect to provide additional updates on the strategic alternatives process that is being run with assistance from our exclusive financial advisor, Piper Sandler & Co. ("Piper Sandler"), as well as data updates on our clinical trials of WTX-124 and WTX-330.

Source filing

WTX-1011 — IND submission

mid-2027

Next milestones: INDs for WTX-1011 and WTX-2022 anticipated in mid-2027

Source filing

WTX-2022 — IND submission

mid-2027

Next milestones: INDs for WTX-1011 and WTX-2022 anticipated in mid-2027

Source filing

neridronate — Topline data

2028

Ambros Therapeutics anticipates reporting topline data from CRPS-RISE in 2028.

Source filing

Explore the free biotech catalyst calendar